Haematology Research

The Concord Haematology Department delivers world-class tertiary Haematology clinical care, supported by active clinical, translational, and basic research. As one of the largest Haematology Clinical Research Units in NSW, we have recruited over 1000 patients to more than 140 trials since 2005.

Our Clinical Research Unit is led by Dr Nicole Wong Doo (Director) and Jennfer Harman (Manager). Our unit is staffed by a Clinical Coordination Division of five Registered Nurses and five Clinical Research Coordinators, all with tertiary science qualifications. Our highly skilled Business Operations Division efficiently meet our regulatory and reporting obligations, and support the team in various high-level administrative functions, in clinical trials governance and financial management. Ten haematologist investigators are supported by several clinical research fellows.

Our broad portfolio with 28 currently recruiting trials and 32 trials in follow-up is particularly strong in trials in lymphoproliferative diseases. As a national leader in accessing emerging therapies, our unit has a high proportion of patients referred for clinical trial participation both within Sydney and across NSW and ACT.

Our Key Research Themes and Achievements

Australasian Leukaemia Lymphoma Group (ALLG) studies

Basic and translational research

ClinTrial Refer App

Engaging medical students in research

High impact publications

International Waldenström Macroglobulinaemia (WM) Study

Leadership in clinical trials

Patient-reported outcomes research, cancer survivorship and patterns of care research

Promoting research with patient organisations

Patient and Community Philanthropic Support

The Haematology Clinical Research Unit is supported by the Foundation for a Bloody Great Cause and their fundraising arm, the Bloody Great Committee. On 18 October 2024, the signature fundraising event, A Bloody Great Night Out!, was held and was a great success with over $300,000 raised for the CRU. The money raised will contribute to the salary of research nurses and research fellows who are critical in delivering highly innovative trials with care and expertise, to our patients. The night also represents our deepening ties with the Concord community who continue to be major supporters.

MyHodgkin MyHealth

Help advance Hodgkin lymphoma research

Are you a patient with Hodgkin lymphoma, either now or in the past?

If so, join us to test the MyHodgkin MyHealth App to improve understanding of the long-term consequences of Hodgkin lymphoma treatments.

Long-term survival rates for people diagnosed with Hodgkin lymphoma are better than ever, but with significant changes to treatment over the last decade, more information is needed to further understand the longer-term consequences of these treatments.
Find out more

Our Research Team

Dr Emma Verner	Head of Department, Consultant Haematologist
Dr Nicole Wong Doo	Haematology Clinical Research Unit Director, Consultant Haematologist
Professor Judith Trotman	Consumer Engagement Lead, Consultant Haematologist
Associate Professor Vivien Chen	Head of Basic and Translational Research, Consultant Haematologist
Associate Professor Ilona Cunningham	Consultant Haematologist
Dr Robin Gasiorowski	Deputy Head of Department, Consultant Haematologist
Dr Janlyn Falconer	Director of Bone Marrow Transplant and Apheresis Unit, Consultant Haematologist
Dr Ibrahim Tohidi-Esfahani	Consultant Haematologist
Dr Marc Ellis	Consultant Haematologist
Dr Riana van der Linde	Head of Laboratory Haematology, Laboratory Haematologist
Dr Ryan Low	Clinical Trials Fellow
Dr Angeline Josiah	Lymphoma Fellow
Jennifer Harman	Clinical Research Unit Manager, Registered Nurse
Palak Shukla	Clinical Research Unit Deputy Manager
Adeline Kintono	Clinical Trial Registered Nurse
Alexander Wong	Clinical Trial Coordinator
Andrea Salangsang	Clinical Trial Registered Nurse
Hengkang Yan	Clinical Trial Coordinator
Mili Patel	Clinical Trial Coordinator
Nathan Zhou	Clinical Trial Coordinator
Nicola Spinola	Clinical Trial Registered Nurse
Toni Poletto	Clinical Trial Registered Nurse
Trieu Huynh	Clinical Trial Registered Nurse
Georgia Klemm	Start Up Manager
Alfredo Inton	Administration Officer
Amanda Li	Administration Officer
Ekaterina Jebelev	Administration Officer
Tess Leavitt	Administration Officer

Selected Grants

Amount awarded	Grant and project details
$2,900,000	MRFF Coronavirus Research Response, 2021-2024 A national, multi-centre study evaluating Thrombotic Thrombocytopenia Syndrome (TTS) associated with ChAdOx1 (AZD1222) and other SARS-CoV-2 vaccines (viral vector & m-RNA) Investigators: Tran (CIA), Chen VM (CIB).
$659,293	MRFF Cardiovascular Health, 2022-2024 Discovery of new platelet targets to improve the management of coronary artery disease. Investigators: Passam F (CIA), Chen VM (CIC).
$193,000	NFMRI, 2022-2024 Novel Biomarker to predict thrombotic risk in myeloproliferative neoplasms. Investigator: Chen V (CIA).
$1,057,839	MRFF International Clinical Trial Collaborations, 2020-2024 Apixaban Twice Daily vs Rivaroxaban Once Daily for the Treatment of Venous Thromboembolism: A randomised controlled trial (COBRRA). Investigator: Chen VM (CIA).
$1,000,000	NSW Cardiovascular Collaborative Grant, 2023-2025 Mechanisms of Vascular Thrombosis. Investigator: Chen VM (CIA).
$500,000	NSW OHMR Translational Research, 2024-2026 A standardised pathway for the management of platelet-related bleeding in NSW. Investigators: Stevenson W (CIA), Chen VM (CIB).
$60,000	University of Sydney Faculty of Medicine and Health, 2024 Rewarding Research Success. Investigator: Chen VM (CIA).
$75,000	National Heart Foundation of Australia Vanguard Grant, 2024-2025 Mapping the platelet phenotype in elderly patients with coronary artery disease. Investigators: Kritharides L (CIA), Chen VM (CIC).
$324,812	MRFF Consumer Led Research, 2024-2027 Using Waldenström's Macroglobulinemia patient-driven research and patient-derived data to increase knowledge of therapy options and quality of life in a rare disease. Investigators: Tohidi-Esfahani I (CIA), Trotman J (CIE).
$787,069	MRFF Rare Cancers, Rare Diseases and Unmet Need, 2019-2024 PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma. Investigator: Trotman J (CIA).
$1,395,000	MRFF, 2021-2026 RADAR: A randomised PET-adapted study of bleomycin-free treatment of early-stage Hodgkin Lymphoma. Investigators: Trotman J, Wong Doo N, Radford J, Berkahn L, Barrington S, Gandhi M, Opat S, Hawkes E, Cochrane T, Johnston A
$2,752,967	MRFF, 2022-2026 Comparing Immunisation-boosting Regimens for COVID-19 Upon Initiation of immunosuppressive Therapies (CIRCUIT Study). Investigators: Sasson S, Kelleher A, Petoumenos K, Davenport M, Trotman J, Brilot F, Turville S, Hamad N, Bull R, Ahlenstiel G

Our Publications

2024

Lee C, Huguenin Y, Pillois X, Moulieras M, Marcy E, Whittaker S, Chen VM, Fiore M.
In vitro characterization of rare anti-αIIbβ3 isoantibodies produced by patients with Glanzmann thrombasthenia that severely block fibrinogen binding and generate procoagulant platelets via complement activation.
Research and Practice in Thrombosis and Haemostasis 1/01/2024, 8(1): 102253, https://doi.org/10.1016/j.rpth.2023.102253

Luminari S, Fossa A, Trotman J, Molin D, d'Amore F, Enblad G, Berkahn L, Barrington S, Radford J, Federico M, Kirkwood A, Johnson P.
Long-term follow-up of the response-adjusted therapy for advanced Hodgkin lymphoma trial.
Journal of Clinical Oncology, 1/01/2024, 42(1): 13-18, https://doi.org/10.1200/JCO.23.01177

Cottereau A, Rebaud L, Trotman J, Feugier P, Nastoupil L, Bachy E, Flinn I, Haioun C, Ysebaert L, Bartlett H, Tilly H, Casasnovas O, Ricci R, Portugues C, Buvat I, Meignan M, Morschhauser F.
Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial.
Annals of Oncology, 1/01/2024, 35(1): 130-137, https://doi.org/10.1016/j.annonc.2023.10.121

Arzivian A, Jones B, Joshua F, Paul M, Lynch T, Brown, Gasiorowski R.
Fever and Increased Gastrointestinal Uptake on Positron Emission Tomography after Anti-Tumour Necrosis Factor Therapy: A Case Report of Whipple’s Disease.
Case Reports in Gastroenterology, 4/01/2024, 18(1): 221-230, https://doi.org/10.1159/000538462

Odutola M, van Leeuwen M, Bruinsma F, Turner J, Hertzberg M, Seymour J, Prince H, Trotman J, Verner E, Roncolato F, Opat S, Lindeman R, Tiley C, Milliken S, Underhill C, Benke G, Giles G, Vajdic C.
A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk.
Cancer Epidemiology, Biomarkers and Prevention , 9/01/2024, 33(1): 106-116, https://doi.org/10.1158/1055-9965.EPI-23-0578

Di Ciaccio P, Polizzotto M, Cwynarski K, Gerrie A, Burton C, Bower M, Kuruvilla J, Montoto S, McKay P, Fox C, Milliken S, Jiamsakul A, Osborne W, Collins G, Manos K, Linton K, Iyengar S, Kassam S, Limei MP, Kliman D, Wong Doo N, Watson A, Fedele P, Yannakou C, Hunt S, Ku M, Sehn L, Smith A, Renshaw H, Maxwell A, Liu Q, Dhairyawan R, Ferguson G, Pickard K, Painter D, Thakrar N, Song K, Hamad N.
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma.
Blood, 11/01/2024, 143(2): 152-165, https://doi.org/10.1182/blood.2023021348

Ninkovic S, Harrison S, Lee J, Murphy N, Lee JH, Estell J, Chen VM, Horvath N, Kim K, Eek R, Augustson B, Bang S, Huang S, Rajagopal R, Szabo F, Engeler D, Butcher B, Mollee P, Durie B, Chng WJ, Quach H.
Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 study.
Haematologica, 18/01/2024, 109(7): 2229-2238, https://doi.org/10.3324/haematol.2023.284238

McQuilten Z, Heritier S, Fox L, Fox V, Young L, Blombery P, Cunningham I, Curnow J, Higgins A, Hiwase D, Filshie R, Firkin F, Lacaze P, Mason K, Mills A, Pepperell D, Patil S, Stevenson W, Szer J, Waters N, Wilson K, Ting S, Wood E.
Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials.
BMJ Open, 19/01/2024, 14(1):e076246, https://doi.org/10.1136/bmjopen-2023-076246

Ellis M, Terreaux A, Alwis I, Smythe R, Perdomo J, Eckly A, Cranmer S, Passam F, Maclean J, Schoenwaelder S, Ruggeri Z, Lanza F, Taoudi S, Yuan Y, Jackson S.
GPIbα–filamin A interaction regulates megakaryocyte localization and budding during platelet biogenesis.
Blood, 25/01/2024, 143(4): 342-356, https://doi.org/10.1182/blood.2023021292

Tohidi-Esfahani I, Mittal P, Isenberg D, Cohen H, Efthymiou M.
Platelets and Thrombotic Antiphospholipid Syndrome.
Journal of Clinical Medicine, 27/01/2024, 13(3): 741, https://doi.org/10.3390/jcm13030741

Campbell A, The B, Mulligan S, Ross D, Weinkove R, Gilroy M, Gangatharan S, Prince H, Szer J, Trotman J, Lane S, Dickinson M, Quach H, Enjeti A, Ku A, Gregory G, Hapgood G, Ho P, Cochrane T, Cheah C, Greenwood M, Latimer M, Berkahn L, Wight J, Armytage T, Diamond P, Tam C, Hamad N.
Australia and New Zealand consensus position statement: use of COVID‐19 therapeutics in patients with haematological malignancies.
Internal Medicine Journal, 1/02/2024, 54(2): 328-336, https://doi.org/10.1111/imj.16303

Wilson M, Kirkwood A, Wong Doo N, Soussain C, Choquet S, Lees C, Fox C, Preston G, Ahearne M, Strüßmann T, Clavert A, Rusconi C, Ku M, Khwaja J, Narkhede M, Lewis K, Durot E, Smith J, Renaud L, Ferreri A, El-Galaly T, Cwynarski K, McKay P, Eyre T.
Dosage of high-dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse.
American Journal of Hematology, 1/02/2024, 99(2): 46-50, https://doi.org/10.1002/ajh.27167

Pott C, Jurinovic V, Trotman J, Kehden B, Unterhalt M, Herold M, van der Jagt R, Janssens A, Kneba M, Mayer J, Young M, Schmidt C, Knapp A, Nielsen T, Brown H, Spielewoy N, Harbron C, Bottos A, Mundt K, Marcus R, Hiddemann W, Hoster E.
Minimal residual disease status predicts outcome in patients with previously untreated follicular lymphoma: a prospective analysis of the phase III GALLIUM Study.
Journal of Clinical Oncology, 10/02/2024, 42(5): 550-561, https://doi.org/10.1200/JCO.23.00838

Sargent Binkley M, Flerlage J, Savage K, Akhtar S, Steiner R, Zhang XY, Dickinson M, Prica A, Major A, Hendrickson P, Hopkins D, Ng A, Casulo C, Baron J, Roberts K, Al Kendi K, Balogh A, Ricardi U, Torka P, Specht L, De Silva R, Pickard K, Blazin L, Henry L, Smith C, Halperin D, Brady J, Brennan B, Anatolevna Senchenko M, Reeves M, Hoppe B, Terezakis S, Talaulikar D, Picardi M, Kirova Y, Fergusson P, Hawkes E, Lee D, Wong Doo N, Barraclough A, Cheah C, Ku M, Hamad N, Mutsando H, Gilbertson M, Marconi T, Viiala N, Maurer N, Eichenauer D, Hoppe R, GLOW Consortium.
International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma.
Journal of Clinical Oncology, 1/03/2024, 42(19), https://doi.org/10.1200/JCO.23.01655

Zlamal J, Aliotta A, Alberio, Chen VM, Bakchoul T, Nazy I, Al-Samkari H, McKenzie S, Pouplard C, Sharma R.
Diagnostic value of antibody-induced procoagulant platelets in heparin-induced thrombocytopenia: communication from the ISTH SSC Subcommittee on Platelet Immunology.
Journal of Thrombosis and Haemostasis, 01/03/2024, 22(3): 860-868, https://doi.org/10.1016/j.jtha.2023.11.019

Schönborn L, Pavord S, Chen VM, Pai M, Haliru Gwarzo D, Buttery J, Munoz F, Tran H, Greinacher A, Law B.
Thrombosis with thrombocytopenia syndrome (TTS) and vaccine-induced immune thrombocytopenia and thrombosis (VITT): Brighton Collaboration case definitions and guidelines for data collection, analysis, and presentation of immunisation safety data.
Vaccine, 7/03/2024, 42(7): 1799-1811, https://doi.org/10.1016/j.vaccine.2024.01.045

Venturelli V, Maranini B, Tohidi-Esfahani I, Isenberg D, Cohen H, Efthymiou M.
Can complement activation be the missing link in antiphospholipid syndrome?
Rheumatology, 14/03/2024, 63(12): 3243-3254, https://doi.org/10.1093/rheumatology/keae178

Reardon B, Hsu J, Smith S, van der Linde R, Brown D, Tegg E, Sasson S. Anti-JOVI.1 antibody to detect clonal T cell populations: implementation into a diagnostic flow cytometry laboratory and correlation with clinical findings.
MedRxiv, 22/03/2024, https://doi.org/10.1101/2024.03.20.24304408

Civallero M, Schroers‐Martin J, Horwitz S, Manni M, Stepanishyna Y, Cabrera M, Vose J, Spina M, Hitz F, Nagler A, Montoto S, Chiattone C, Skrypets T, Perez Saenz M, Priolo G, Luminari S, Lymboussaki A, Pavlovsky A, Marino D, Liberati M, Trotman J, Mannina D, Federico M, Advani R.
Long‐term outcome of peripheral T‐cell lymphomas: Ten‐year follow‐up of the International Prospective T‐cell Project.
British Journal of Haematology, 26/03/2024, 205(1): 166-174, https://doi.org/10.1111/bjh.19433

Tiong I, Wall M, Bajel A, Kalro A, Fleming S, Roberts A, Thiagarajah N, Chua C, Latimer M, Yeung D, Marlton P, Johnston A, Enjeti A, Fong C, Cull G, Larsen S, Kennedy G, Schwarer A, Kipp D, Ramanathan S, Verner E, Tiley C, Morris E, Hahn U, Moore J, Taper J, Purtill D, Warburton P, Stevenson W, Murphy N, Tan P, Beligaswatte A, Mutsando H, Hertzberg M, Shortt J, Szabo F, Dunne K, Wei A, Australasian Leukaemia and Lymphoma Group (ALLG).
How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials?
Blood Cancer Journal, 26/03/2024, 14(1): 54, https://doi.org/10.1038/s41408-024-00996-x

Tam C, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen R, Marlton P, Wahlin B, García-Sanz R, McCarthy H, Mulligan S, Tedeschi A, Castillo J, Czyż, Fernández De Larrea C, Belada D, Libby E, Matous J, Motta M, Siddiqi T, Tani M, Trněný M, Minnema M, Buske C, Leblond V, Treon S, Trotman J, Wu B, Yu Y, Shen Z, Chan W, Schneider J, Allewelt H, Cohen A, Dimopoulos M.
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Blood Advances, 9/04/2024, 8(7): 1639-1650, https://doi.org/10.1182/bloodadvances.2023010906

McQuilten Z, Weinkove R, Thao L, Crispin P, Degelia A, Dendle C, Gilbertson M, Johnston A, Keegan A, Pepperell D, Pullon H, Reynolds J, van Tonder T, Trotman J, Waters N, Wellard C, Weston H, Morrissey C, Wood E.
Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy.
Blood Advances, 9/04/2024, 8(7): 1787-1795, https://doi.org/10.1182/bloodadvances.2023011231

Camus V, Thieblemont C, Gaulard P, Cheminant M, Casasnovas R, Ysebaert L, Damaj G, Guidez S, Pica G, Kim WS, Lim ST, Andre M, Gutiérrez N, Penarrubia M, Staber P, Trotman J, Hüttmann A, Stefoni V, Tucci A, Fogarty P, Farhat H, Abraham J, Abarah W, Belmecheri F, Ribrag V, Delfau-Larue M, Cottereau A, Itti E, Li J, Delarue R, de Leval L, Morschhauser F, Bachy E.
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone VersusCyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.
Journal of Clinical Oncology, 10/05/2024, 42(14): 1612-1618, https://doi.org/10.1200/JCO.23.01687

Carrillo de Albornoz S, Higgins A, Petrie D, Irving A, Fanning L, Weinkove R, Crispin P, Dendle C, Gilbertson M, Johnston A, Keegan A, Pepperell D, Pullon H, Reynolds J, van Tonder T, Trotman J, Waters N, Wellard C, Weston H, Morrissey C, Wood E, McQuilten Z.
Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies.
Blood Advances, 14/05/2024, 8(9): 2259-2267, https://doi.org/10.1182/bloodadvances.2023012047

Mittal P, Gafoor R, Sayar Z, Efthymiou M, Tohidi-Esfahani I, Appiah-Cubi S, Arachchillage D, Atkinson D, Bordea E, Cardoso J, Caverly E, Chandratheva A, Chau M, Freemantle N, Gates C, Jager H, Kaul A, Mitchell C, Nguyen H, Packham B, Paskell J, Patel J, Round C, Sanna G, Zaidi A, Werring D, Isenberg D, Cohen H.
Rivaroxaban for stroke patients with antiphospholipid syndrome (RISAPS): protocol for a randomized controlled, phase IIb proof-of-principle trial.
Research and Practice in Thrombosis and Haemostasis, 1/07/2024, 8(5): 102468, https://doi.org/10.1016/j.rpth.2024.102468

Tobin J, Hapgood G, Johnston A, Cheah C, Lee Z, Trotman J, Inam S, Campbell B, Norris D, MacManus M, Hertzberg M, Hawkes E.
Diagnosis, management and follow‐up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.
Internal Medicine Journal, 1/08/2024, 54(8): 1384-1395, https://doi.org/10.1111/imj.16454

Ho P, Spencer A, Mollee P, Bryant C, Enjeti A, Horvath N, Butcher B, Trotman J, Gibbs S, Joshua D.
Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment—An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and Relapse.
Clinical Lymphoma Myeloma and Leukemia, 1/08/2024, 24(8): 491-564, https://doi.org/10.1016/j.clml.2024.04.001

Tedeschi A, Tam C, Owen R, Buske C, Leblond V, Dimopoulos M, Garcia-Sanz R, Castillo J, Trotman J, Treon S, Yang K, Tang B, Allewelt H, Patel S, Chan W, Cohen A, Chen S, Barnes G.
Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial.
Future Oncology, 8/08/2024, 20(25): 1789-1798, https://doi.org/10.1080/14796694.2024.2355079

Zinzani P, Muñoz J, Trotman J.
Current and future therapies for follicular lymphoma.
Experimental Hematology & Oncology, 22/08/2024, 13(1): 87, https://doi.org/10.1186/s40164-024-00551-1

Trotman J, Barrington S.
Interpreting Baseline PET Metrics and PET-Based Response in Lymphoma.
Clinical Lymphoma Myeloma and Leukemia, 1/09/2024, 24: S39-S40, https://doi.org/10.1016/S2152-2650(24)00339-2

Thieblemont C, Karimi Y, Ghesquieres H, Cheah C, Clausen M, Cunningham D, Jurczak W, Do Y, Gasiorowski R, Lewis D, Kim T, van der Poel M, Poon M, Feldman T, Linton K, Sureda A, Hutchings M, Dinh M, Kilavuz N, Soong S, Mark T, Sacchi M, Phillips T, Lugtenburg P.
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial.
Leukemia, 25/09/2024, 38: 2653-2662, https://doi.org/10.1038/s41375-024-02410-8

Li E, Jones E, Bryant C, King T, Talaulikar D, Ng J, Bryant A, Ridha Z, Wong Doo N, Menzies A, Ling S, Ho S, Abadir E, Vanguru V, Joshua D, Ho P.
A single‐day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies.
European Journal of Haematology, 1/10/2024, 113(4): 521-529, https://doi.org/10.1111/ejh.14266

Revoltar M, van der Linde R, Cromer D, Gatt P, Smith S, Fernandez M, Vaughan L, Blyth E, Curnow J, Tegg E, Brown D, Sasson S.
Indeterminate measurable residual disease by multiparameter flow cytometry is associated with an intermediate risk of clinical relapse in adult patients with acute leukaemia.
Pathology, 1/10/2024, 56(6): 882-888, https://doi.org/10.1016/j.pathol.2024.04.009

Barraclough A, Agrawal S, Talaulikar D, Chong G, Yoo E, Cheah C, Franco N, Nguyen B, Mutsando H, Tahir F, Trotman J, Huang J, Keane C, Lincoln M, Cochrane T, Johnston A, Dickinson M, Opat S, McQuilten Z, Wood E, St George G, Hawkes E.
Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study.
Haematologica, 10/10/2024, 109(10): 3338, https://doi.org/10.3324/haematol.2023.284538

Amaador K, Thieblemont C, Trotman J, Minnema M.
Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström's macroglobulinemia.
Hematological Oncology, 1/11/2024, 42(4): e3210, https://doi.org/10.1002/hon.3210

Gunawardana J, Law S, Sabdia M, Fennell E, Hennessy A, Leahy C, Murray P, Bednarska K, Brosda S, Trotman J, Berkahn L, Zaharia A, Birch S, B Murgess, Talaulikar D, Lee J, Jude E, Hawkes E, Jain S, Nath K, Snell C, Swain F, Tobin J, Keane C, Shanavas M, Blyth E, Steidl C, Savage K, Farinha P, Boyle M, Meissner B, Green M, Vega F, Gandhi M.
Intra‐tumoral and peripheral blood TIGIT and PD‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma.
American Journal of Hematology, 1/11/2024, 99(11): 2096-2107, https://doi.org/10.1002/ajh.27459

Trotman J, Zinzani P, Song Y, Delarue R, Kim P, Ivanova E, Korde R, Mayer J, De Oliveira A, Assouline S, Flowers C, Barnes G.
Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trial.
Current Medical Research and Opinion, 1/11/2024, 40(11): 1863-1871, https://doi.org/10.1080/03007995.2024.2409837

Trotman J, LaCasce A, Osborne W, Steiner A, Hawkes E, Casulo C, Women in Lymphoma Steering Committee.
Women in Lymphoma: A 4‐year journey in promoting gender equity.
Hematological Oncology, 1/11/2024, 42(6): 3183, https://doi.org/10.1002/hon.3183

Yeung D, Shanmuganathan N, Reynolds J, Branford S, Walia M, Yong A, Shortt J, Chee L, Viiala N, Cunningham I, Ross D, D’Souza A, Wright M, Harrup R, Forsyth C, Filshie R, Lane S, Browett P, Grove C, Grigg A, Hughes T.
Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study.
Blood, 7/11/2024, 144(19): 1993-2001, https://doi.org/10.1182/blood.2024024657

Verner E, Johnston A, Pati N, Hawkes E, Lee H, Cochrane T, Cheah C, Filshie R, Purtill D, Sia H, Enjeti A, Brown C, Murphy N, Curnow J, Lee K, Gandhi M, Walia M, Butcher B, Trotman J.
Ibrutinib plus rituximab and mini-CHOP in older patients with newly diagnosed DLBCL: a phase 2 ALLG study.
Blood Advances, 12/11/2024, 8(21): 5674-5682, https://doi.org/10.1182/bloodadvances.2024014035

Huang W, Law B, Tran H, Schönborn L, Huang W, Buttery J, Chen VM, Greinacher A, Pavord S.
Validation of the newly proposed Brighton Collaboration case definition for vaccine-induced immune thrombocytopenia and thrombosis.
Vaccine, 14/11/2024, 42(25):126131, https://doi.org/10.1016/j.vaccine.2024.07.032

Heyman B, Opat S, Wahlin B, Dimopoulos M, Castillo J, Tedeschi A, Tam C, Buske C, Owen R, Leblond V, Trotman J, Barnes G, Chan W, Schneider J, Allewelt H, Cohen A, Matous J.
Peripheral Neuropathy in the Phase 3 ASPEN Study of Bruton Tyrosine Kinase Inhibitors for Waldenström Macroglobulinemia.
Blood Advances, 5/12/2024, Epub ahead of print., https://doi.org/10.1182/bloodadvances.2024014115

Trotman J, Falconer J.
In pursuit of a functional cure for follicular lymphoma.
Hematology Am Soc Hematol Educ Program, 6/12/2024, 2024(1): 293-300, https://doi.org/10.1182/hematology.2024000654

Shadman M, Munir T, Robak T, Brown J, Kahl B, Ghia P, Giannopoulos K, Šimkovič M, Österborg A, Laurenti L, Walker P, Opat S, Ciepluch H, Greil R, Hanna M, Tani M, Trněný M, Brander D, Flinn I, Grosicki S, Verner E, Tedeschi S, de Guibert S, Tumyan G, Laribi K, García-Marco J, Li J, Tian T, Liu Y, Korolkiewicz R, Szeto A, Tam C, Jurczak W.
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.
Journal of Clinical Oncology, 8/12/2024, 43(7), https://doi.org/10.1200/JCO-24-02265

Tan S, Turner J, Kerin‐Ayres K, Hewitt L, Butler S, Deguchi C, Khatri S, Wildbore C, Cunningham I, Dhillon H, Malalasekera A, Vardy J.
Completion Rate of Paper‐Based and Electronic Patient Reported Outcome Measures in a Multidisciplinary Cancer Survivorship Clinical Setting.
Asia‐Pacific Journal of Clinical Oncology, 15/12/2024, Epub ahead of print. PMID: 39676326, https://doi.org/10.1111/ajco.14146

Tobin J, Chikatamarla V, Matic M, Griffin A, Chowdhury R, Salvaris R, Goh A, Black H, Tong H, Birks C, Jain S, Goodall E, Sirdesai S, Trevis T, Steinepreis E, Chen Y, Li L, Broadby G, Gutta G, Morris K, Cochrane T, Trotman J, Talaulikar D, Shortt J, Hodges G, Hawkes E, Cheah C, Barraclough A, Manos K, Johnston A, Royle J, Mondello P, Ansell S, Hapgood G.
Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy.
Blood Neoplasia, 16/12/2024, 1(4): 100044, https://doi.org/10.1016/j.bneo.2024.100044

Zlamal J, Ripoll V, Lee C, Toma F, Althaus K, Rigoni F, Witzemann A, Whittaker S, Capraro D, Uzun G, Bakchoul T, Chen VM.
Platelet spleen tyrosine kinase is a key regulator of anti-PF4 antibody-induced immunothrombosis.
Blood Advances, 24/12/2024, Epub ahead of print, https://doi.org/10.1182/bloodadvances.2024014167

2023

Choi PY, Hsu D, Tran HA, Tan CW, Enjeti A, Chen VM, Merriman E, Yong AS, Simpson J, Gardiner E, Cherbuin N, Curnow J, Pepperell D, Bird R.
Immune thrombocytopenia and COVID-19 vaccination: Outcomes and comparisons to prepandemic patients.
Research and Practice in Thrombosis and Haemostasis. 2023 Jan 1;7(1):100009. https://doi.org/10.1016/j.rpth.2022.100009

Phillips K, Rijal S, Smyth L, Handunnetti S, Ngo C, Verner E, Trotman J, Agrawal S, Tatarczuch M, Tam C, Man SM.
Impact of BTKI use in haematologic malignancies on inflammatory response signatures.
International Journal of Laboratory Hematology. 2023 Jan 1; 4: 136-136. https://doi.org/10.1111/ijlh.14006

Rijal S, Lim JH, Smyth L, Coombes C, Jain S, Saxena K, Trotman J, Verner E, Gandhi MK, Gandhi K, Talaulikar D.
Analysis of the genetic landscape in elderly diffuse large b cell lymphoma aged>= 75 years identifies new targetable mutations.
International Journal of Laboratory Hematology. 2023 Jan 01; 45: 148-148. https://doi.org/10.1111/ijlh.14006

Odutola MK, van Leeuwen MT, Bassett JK, Bruinsma F, Turner J, Seymour JF, Prince HM, Milliken ST, Hertzberg M, Roncolato F, Opat SS, Lindeman R, Tiley C, Trotman J, Verner E, Harvey M, Underhill CR, Benke G, Giles GG, Vajdic CM.
Dietary intake of animal-based products and likelihood of follicular lymphoma and survival: A population-based family case-control study.
Frontiers in Nutrition. 2023 Jan 4; 9:1048301. https://doi.org/10.3389/fnut.2022.1048301

Pennings GJ, Reddel CJ, Chen VM, Gnanenthiran SR, Kritharides L.
Perspective: Collagen induced platelet activation via the GPVI receptor as a primary target of colchicine in cardiovascular disease.
Frontiers in Cardiovascular Medicine. 2023 Jan 19;9:1104744. https://doi.org/10.3389/fcvm.2022.1104744

Selvadurai MV, Favaloro EJ, Chen VM.
Mechanisms of thrombosis in heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia.
Seminars in Thrombosis and Hemostasis. 2023 Jan 27; 49(05): 444-452 https://doi.org/10.1055/s-0043-1761269

Tariq B, Ou YC, Stern JC, Mundra V, Wong Doo N, Walker P, Lewis KL, Lin C, Novotny W, Sahasranaman S, Opat S.
A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies.
Leukemia and Lymphoma. 2023 Jan 28;64(2):329-338. https://doi.org/10.1080/10428194.2022.2150820

Tohidi‐Esfahani I, Trotman J.
Dose of ibrutinib in Waldenström macroglobulinaemia: Less can be more.
British Journal of Haematology. 2023 Jan 30; 201(5):807-808. https://doi.org/10.1111/bjh.18664

Beaton B, Sasson SC, Rankin K, Raedemaeker J, Wong A, Hastak P, Phetsouphanh C, Warden A, Klemm V, Munier CML, Hoppe AC, Tea F, Pillay A, Stella AO, Aggarwal A, Lavee O, Caterson ID, Turville S, Kelleher AD, Brilot F, Trotman J.
Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti-spike neutralizing IgG to SARS-CoV-2 variants, but preserved antigen-specific T cell responses.
American Journal of Hematology. 2023 Jan;98(1):131-139. https://doi.org/10.1002/ajh.26619

Perram J, Purtill D, Bajel A, Butler J, O'Brien T, Teh B, Gilroy N, Ho PJ, Doocey R, Hills T, Perera T, Douglas G, Ramachandran S, Chee L, Trotman J, Weinkove R, Keogh S, Fraser C, Cochrane T, Watson AM, Diamond P, Latimer M, Irving I, Blyth E, Cheah C, Cole T, Milliken S, Yang H, Greenwood M, Bardy P, Kennedy G, Larsen S, Conyers R, Hamad N.
Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID‐19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell.
Internal Medicine Journal. 2023 Jan; 53(1):119-125. https://doi.org/10.1111/imj.15978

Ricard F, Cheson B, Barrington S, Trotman J, Schmid A, Brueggenwerth G, Salles G, Schwartz L, Goldmacher G, Jarecha R, Narang J, Broussais F, Galette P, Liu M, Bajpai S, Perlman E, Gillis J, Smalberg I, Terve P, Zahlmann G, Korn R.
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1-Clinical).
Journal of Nuclear Medicine. 2023 Jan;64(1):102-108. https://doi.org/10.2967/jnumed.122.264106

Yeung J, Dix CHK, Ritchie AG, Kow M, Chen VMY.
Tinzaparin for venous thromboembolism in patients with renal impairment: a single-centre, prospective pilot study.
Internal Medicine Journal. 2023 Jan;53(1):68-73. https://doi.org/10.1111/imj.15010

Reardon B, Smith S, Van Der Linde R, Sasson SC.
Use of anti-JOVI. 1 antibodies to detect clonal T cell populations: implementation into a diagnostic flow cytometry laboratory and correlation with clinical findings.
Pathology. 2023 Feb 1;55(1):S23. https://doi.org/10.1016/j.pathol.2022.12.077

Ricard F, Barrington S, Korn R, Brueggenwerth G, Trotman J, Cheson B, Salles G, Schwartz L, Goldmacher G, Jarecha R, Narang J, Broussais F, Galette P, Liu M, Bajpai S, Perlman E, Gillis J, Smalberg I, Terve P, Zahlmann G, Schmid A.
Application of the Lugano classification for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the PRoLoG consensus initiative (part 2-technical).
Journal of Nuclear Medicine. 2023 Feb 1; 64(2):239-243. https://doi.org/10.2967/jnumed.122.264124

Trotman J, Presgrave P, Carradice DP, Lenton DS, Gandhi MK, Cochrane T, Badoux X, Carlson J, Nkhoma G, Butcher B, Nikpour A, Fulham M, Johnston AM.
Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study.
Hemasphere. 2023 Feb 21;7(3):e836. https://doi.org/10.1097/HS9.0000000000000836

Baggio D, Wellard C, Chung E, Talaulikar D, Keane C, Opat S, Giri P, Minson A, Cheah CY, Armytage T, Lee D, Chong G, Johnston A, Cochrane T, Waters N, Hamad N, Wood EM, Hawkes EA, Balendra J, Barraclough A, Berkahn L, Bosco A, Carradice D, Chuah H, Coyle L, Crassini K, Kenealy M, Ku M, Leung T, Manos K, Morgan S, Mutsando H, Narayana M, Palfreymen E, Prince M, Ratnasingam S, Simpson J, Trotman J, Viiala N, Wight J.
Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry.
Leukemia and Lymphoma. 2023 Feb 23;64(3):621-627. https://doi.org/10.1080/10428194.2022.2157676

Buske C, Tedeschi A, Trotman J, García-Sanz R, MacDonald D, Leblond V, Mahe B, Herbaux C, Matous JV, Tam CS, Heffner LT, Varettoni M, Palomba ML, Shustik C, Kastritis E, Treon SP, Ping J, Hauns B, Arango-Hisijara I, Dimopoulos MA.
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia.
Future Oncology. 2023 Feb; 19(5):345-353. https://doi.org/10.2217/fon-2022-1015

Castillo JJ, Buske C, Trotman J, Sarosiek S, Treon SP.
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
American Journal of Hematology. 2023 Feb; 98(2):338-347. https://doi.org/10.1002/ajh.26788

Lee CS, Clarke LJ, Kershaw GW, Tohidi-Esfahani I, Brighton TA, Chunilal S, Favaloro EJ, Tran H, Chen VM.
Platelet-activating functional assay resolution in vaccine-induced immune thrombotic thrombocytopenia: differential alignment to PF4 ELISA platforms.
Research and Practice in Thrombosis and Haemostasis. 2023 Mar 1;7(3):100128. https://doi.org/10.1016/j.rpth.2023.100128

Ellis ML, Alwis I, Smythe R, Yuan Y, Jackson SP.
Megakaryocyte buds are distinct from microvesicles and likely to represent platelet precursors.
Blood Advances. 2023 Mar 28;7(6):982-986. https://doi.org/10.1182/bloodadvances.2022008850

Buske C, Castillo JJ, Abeykoon JP, Advani R, Arulogun SO, Branagan AR, Cao X, D'Sa S, Hou J, Kapoor P, Kastritis E, Kersten MJ, LeBlond V, Leiba M, Matous JV, Paludo J, Qiu L, Tam CS, Tedeschi A, Thomas SK, Tohidi-Esfahani I, Varettoni M, Vos JM, Garcia-Sanz R, San-Miguel J, Dimopoulos MA, Treon SP, Trotman J.
Report of Consensus Panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on Management of Symptomatic, Treatment-Naïve Patients.
Seminars in Hematology. 2023 Mar 29; 60(2):73-79. https://doi.org/10.1053/j.seminhematol.2023.03.005

D'Sa S, Matous JV, Advani R, Buske C, Castillo JJ, Gatt M, Kapoor P, Kersten MJ, Leblond V, Leiba M, Palomba ML, Paludo J, Qiu L, Sarosiek S, Shadman M, Talaulikar D, Tam CS, Tedeschi A, Thomas SK , Tohidi-Esfahani I, Trotman J, Varettoni M, Vos JMI, Garcia-Sanz R, San-Miguel J, Dimopoulos MA, Treon SP, Kastritis E.
Report of Consensus Panel 2 from the 11th International Workshop on Waldenström's Macroglobulinemia on the Management of Relapsed or Refractory WM Patients.
Seminars in Hematology. 2023 Mar; 60(2):80-89. https://doi.org/10.1053/j.seminhematol.2023.03.003

Plesner T, Harrison SJ, Quach H, Lee C, Bryant A, Vangsted A, Estell J, Delforge M, Offner F, Twomey P, Choeurng V.
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma.
Clinical Hematology International. 2023 Mar;5(1):43-51. https://doi.org/10.1007/s44228-022-00023-5

Terpos E, Branagan AR, Garcia-Sanz R, Trotman J, Greenberger LM, Stephens DM, Morel P, Kimby E, Frustaci AM, Hatjiharissi E, San-Miguel J, Dimopoulos MA, Treon SP, Leblond V.
Report of Consensus Panel 5 from the 11th International Workshop on Waldenström's Macroglobulinemia on COVID-19 Prophylaxis and Management.
Seminars in Hematology. 2023 Mar; 60(2):107-112. https://doi.org/10.1053/j.seminhematol.2023.03.004

van der Linde R, Smith S, Brown DA, Sasson SC, Tegg E.
Measurable residual disease in adult acute myeloid leukaemia: evaluation of a multidimensional 'radar'flow cytometric plot analysis method.
Pathology. 2023 Apr 1;55(3):383-90. https://doi.org/10.1016/j.pathol.2022.10.007

Nagaratnam S, Harinesan N, Wijesinghe R, Wong Doo N, Lyons A, Morris K, Triplett J.
Painless progressive mononeuritis multiplex secondary to AML associated neuroleukemiosis.
Journal of Neuroimmunology. 2023 Apr 15;377:578061. https://doi.org/10.1016/j.jneuroim.2023.578061

Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Do YR, Feldman T, Gasiorowski R, Jurczak W, Kim TM, Lewis DJ, van der Poel M, Poon ML, Cota Stirner M, Kilavuz N, Chiu C, Sacchi M, Elliott B, Ahmadi T, Hutchings M, Lugtenburg PJ.
Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial.
Journal of Clinical Oncology. 2023 Apr 20;41(12):2238-2247. https://doi.org/10.1200/JCO.22.01725

Mittal P, Quattrocchi G, Tohidi-Esfahani I, Sayar Z, Chandratheva A, Cohen H.
Antiphospholipid syndrome, antiphospholipid antibodies, and stroke.
International Journal of Stroke. 2023 Apr;18(4):383-391. https://doi.org/10.1177/17474930221150349

Narayan SW, Gad F, Chong J, Chen VM, Patanwala AE.
Preventability of venous thromboembolism in hospitalised patients.
Internal medicine journal. 2023 Apr; 53(4):577-583. https://doi.org/10.1111/imj.15600

Nguyen J, Wellard C, Chung E, Cheah CY, Dickinson M, Wong Doo N, Keane C, Talaulikar D, Berkahn L, Morgan S, Hamad N, Cochrane T, Johnston AM, Forsyth C, Opat S, Barraclough A, Mutsando H, Ratnasingam S, Giri P, Wood EM, McQuilten ZK, Hawkes EA.
Clinical characteristics of Australian treatment‐naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry.
European Journal of Haematology. 2023 Apr;110(4):386-395. https://doi.org/10.1111/ejh.13915

Talaulikar D, Joshua D, Ho PJ, Gibson J, Quach H, Gibbs S, Ling S, Ward C, Augustson BM, Trotman J, Harrison SJ, Tam CS.
Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Internal Medicine Journal. 2023 Apr; 53(4):599-609. https://doi.org/10.1111/imj.15980

Lay AJ, Dupuy A, Hagimola L, Tieng J, Larance M, Zhang Y, Yang J, Kong Y, Chiu J, Gray E, Qin Z, Schmidt D, Maclean J, Hofma B, Ellis M, Kalev-Zylinska M, Argon Y, Jackson SP, Hogg P, Passam FH.
Endoplasmic reticulum protein 5 attenuates platelet endoplasmic reticulum stress and secretion in a mouse model.
Blood Advances. 2023 May 9;7(9):1650-1665. https://doi.org/10.1182/bloodadvances.2022008457

Hapgood G, Civallero M, Stepanishyna Y, Vose JM, Cabrera ME, Advani RH, Pileri SA, Manni M, Horwitz SM, Foss FM, Hitz F. Radford J, Dlouhy I, Chiattone C, Kim WS, Skrypets T, Nagler A, Trotman J, Luminari S, Federico M.
The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network.
Blood Advances. 2023 May 10; 7(17):5047-5054. https://doi.org/10.1182/bloodadvances.2023010037

Clarke L, Brighton T, Chunilal SD, Lee CS, Passam F, Curnow J, Chen VM, Tran HA.
Vaccine-induced immune thrombotic thrombocytopenia post dose 2 ChAdOx1 nCoV19 vaccination: Less severe but remains a problem.
Vaccine. 2023 May 11;41(20):3285-3291. https://doi.org/10.1016/j.vaccine.2023.03.071

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Annals of hematology. 2023 May 12; 102:1773-1787. https://doi.org/10.1007/s00277-023-05196-4

Trotman J, LaCasce A, Osborne W, Steiner A, Hawkes E, Casulo C, Broussais F, Casulo C, Cwynarksi K, Ghione P.
Women in Lymphoma: A 4‐year journey in promoting gender equity.
Hematological Oncology. 2023 May 25; 1-5 https://doi.org/10.1002/hon.3183

Baker RI, Gilmore G, Chen V, Young L, Merriman E, Curnow J, Joseph J, Tiao JY, Chih J, McRae S, Harper P, Tan CW, Brighton T, Royle G, Hugman A, Hankey GJ, Crowther H, Boey J, Gallus A, Campbell P, Tran H; Thrombosis and Haemostasis Society of Australia and New Zealand Anticoagulation Reversal and Events Study Collaborative.
Direct oral anticoagulants or vitamin K antagonists in emergencies: comparison of management in an observational study.
Research and Practice in Thrombosis and Haemostasis. 2023 May 26;7(5):100196. https://doi.org/10.1016/j.rpth.2023.100196

Nastoupil LJ, Song Y, Sehn LH, Sarkozy C, Zinzani PL, Salar A, Zhang J, Huang S, Wang J, Delarue R, Trotman J.
MAHOGANY: A Phase 3 Trial of Zanubrutinib Plus Anti-CD20 Antibodies vs Lenalidomide Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal Zone Lymphoma.
Journal of Clinical Oncology. 2023 May 31; 41(16). https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS7590

Li EW, Krishnaswamy M, El-Wahsh S, Balgobind S, Trotman J, Tan I, Hardy TA.
Paraneoplastic primary CNS angiitis secondary to nodular lymphocyte predominant Hodgkin lymphoma.
Pathology. 2023 Jun 1;55(4):547-551. https://doi.org/10.1016/j.pathol.2022.08.012

Karimi Y, Ghesquieres H, Jurczak W, Cheah C, Clausen M, Lugtenburg P, Do YR, Lewis DJ, Gasiorowski R, Kim TM, van der Poel M, Poon MLM, Feldman TA, Linton KM, Sureda A, Hutchings M, Cota Stirner M, Sacchi M, Thieblemont C.
Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial.
Journal of Clinical Oncology. 2023 Jun 01; 41(16), 7525-7525 https://doi.org/10.1200/JCO.2023.41.16_suppl.7525

Defrancesco I, Ferretti VV, Morel P, Kyriakou C, Kastritis E, Tohidi-Esfahani I, Tedeschi A, Buske C, García-Sanz R, Vos JMI, Peri V, Margiotta Casaluci G, Ferrari A, Piazza F, Oostvogels R, Lovato E, Montes L, Fornecker LM, Grunenberg A, Dimopoulos MA, Tam CS, D'Sa S, Leblond V, Trotman J, Passamonti F, Arcaini L, Varettoni M.
SARS-CoV-2 Infection in Patients With Waldenström's Macroglobulinemia: A Multicenter International Cohort Study.
Hemasphere. 2023 Jun 2;7(6):e887. https://doi.org/10.1097/HS9.0000000000000887

Ross DM, Liang HP, Iqra Z, Whittaker S, Tan CW, Dale BJ, Chen VM.
Platelets from patients with myeloproliferative neoplasms have increased numbers of mitochondria that are hypersensitive to depolarization by thrombin.
Scientific Reports. 2023 Jun 6;13(1):9172. https://doi.org/10.1038/s41598-023-36266-2

Minson A, Verner E, Giri P, Wong SM, Ratnasingam S, Butler J, Janowski W, Ku M, Cheah CY, Hertzberg M, Herbert K, Hamad N, Yannakou CK, Neeson P, Saghebi J, Blombery P, Robertson M, Lau LS, Xie J, Seymour JF, Dickinson M.
Glofitamab plus R-CHOP or polatuzumab vedotin-R-CHP is deliverable with high overall response in patients ≤65 years of age with high-risk DLBCL: Interim analysis of COALITION.
Hematological Oncology. 2023 Jun 09; 41: 421-422. https://doi.org/10.1002/hon.3164_309

Trotman J, Zinzani PL, Mayer J, Flowers CR, Bijou F, de Oliveira AC, Bouabdallah K, Johnson R, Garcia-Sancho AM, Pulla MP, Trněný M, Tilly H, Wojiech J, Ivanova E, Kim P, Greenbaum A, Huang S, Delarue R, Auer R.
Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma: Updated Analysis of the ROSEWOOD Study.
Hematological Oncology. 2023 Jun 9; 41(S2):119-121. https://doi.org/10.1002/hon.3163_81

Rankin K, Hastak P, Wong A, Sasson SC, Beaton B, Yeola A, Warden A, Turville S, Kelleher AD, Brilot F, Trotman J.
Immune response to COVID-19 vaccination in patients with Waldenström macroglobulinaemia who pause their BTKi therapy.
European Journal of Haematology. 2023 Jun 21;4(3):728-732. https://doi.org/10.1002/jha2.724

Tam CS, Trotman J, Opat S, Stern JC, Allewelt H, By K, Novotny W, Huang J, Tedeschi A.
Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia.
Blood Advances. 2023 Jun 27;7(12):2884-2887.
https://doi.org/10.1182/bloodadvances.2022008990

Sehn L, Sarkozy C, Song Y, Salar A, Trotman J, Zinzani PL, Zhang J, Zhang W, Fustier P, Delarue R, Nastoupil L.
MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 versus lenalidomide plus rituximab in patients with relapsed/refractory follicular or marginal zone lymphoma.
Hematological Oncology. 2023 Jun; 41:168-170. https://doi.org/10.1002/hon.3163_T04

Townsend W, Hiddemann W, Buske C, Cartron G, Dyer MJ, Gribben JG, Phillips EH, Dreyling M, Seymour JF, Grigg A, Trotman J, Lin TY, Hong XN, Kingbiel D, Nielsen T, Knapp A, Herold M, Marcus R.
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study.
HemaSphere. 2023 Jul 1;7(7):e919. https://doi.org/10.1097/HS9.0000000000000919

Amaador K, Thieblemont C, Trotman J, Minnema MC.
Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström's macroglobulinemia.
Hematological Oncology. 2023 Jul 17; 1-7. https://doi.org/10.1002/hon.3210

Tatarczuch M, Waltham M, Shortt J, Polekhina G, Hawkes EA, Ho SJ, Trotman J, Brasacchio D, Co M, Li J, Ramakrishnan V, Dunne K, Opat SS, Gregory GP.
Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma.
Blood Advances. 2023 Jul 25; 7(14):3531-3539. https://doi.org/10.1182/bloodadvances.2022009412

Zinzani PL, Mayer J, Flowers CR, Bijou F, De Oliveira AC, Song Y, Zhang Q, Merli M, Bouabdallah K, Ganly P, Zhang H, Merli M, Bouabdallah K, Ganly P, Zhang H, Johnson R, Martín García-Sancho A, Provencio Pulla M, Trněný M, Yuen S, Tilly H, Kingsley E, Tumyan G, Assouline SE, Auer R, Ivanova E, Kim P, Huang S, Delarue R, Trotman J. ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
Journal of Clinical Oncology. 2023 Jul 28; JCO-23:1-11. https://doi.org/10.1200/JCO.23.00775

Dimopoulos MA, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Garcia-Sanz R, McCarthy H. Mulligan S, Tedeschi A, Castillo JJ, Czyz J, Fernández de Larrea C, Belada D, Libby E, Matous J, Motta M, Siddiqi T, Tani M, Trněný M, Minnema MC, Buske C, Leblond V, Treon SP, Trotman J, Chan WY, Schneider J, Allewelt H, Patel S, Cohen A, Tam CS.
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.
Journal of Clinical Oncology. 2023 Jul;JCO-22:5099-5106. https://doi.org/10.1200/JCO.22.02830

McKenzie CA, Gupta R, Jackett L, Anderson L, Chen VM, Dahlstrom JE, Dray M, Farshid G, Hemmings C, Karim R, Kench JG, Klebe S, Kramer N, Kumarasinghe P, Maclean F, Morey A, Nguyen MA, O'Toole S, Rowbotham B, Salisbury ELC, Scolyer RA, Stewart K, Waring L, Cooper CL, Cooper WA.
Looking beyond workforce parity: addressing gender inequity in pathology.
Pathology. 2023 Jul; 55(6):760-771. https://doi.org/10.1016/j.pathol.2023.07.002

Tedeschi A, Tam C, Owen R, Buske C, Leblond V, Dimopoulos MA, García-Sanz R, Castillo J, Trotman J, Treon S, Yang K, Tang B, Allewelt H, Patel S, Chan W, Cohen A, Schneider JY, Barnes Gisoo.
P1679: Health-Related Quality Of Life In Patients (Pts) With Waldenström Macroglobulinemia (Wm) Treated With Zanubrutinib (Zanu) Vs Ibrutinib (Ibr): Results From The Phase 3 Aspen Trial Long-Term Follow-Up.
HemaSphere. 2023 Aug 1; 7(S3):e27391ea. https://doi.org/10.1097/01.HS9.0000973588.27391.ea

Adattini JA, Gross AS, Wong Doo N, McLachlan AJ.
Insights into dasatinib use and outcomes in real-world patients with chronic myeloid leukemia.
Haematologica. 2023 Aug 8;108(8): 2224-2228. https://doi.org/10.3324/haematol.2022.282237

Hawkes EA, Trotman J, Casulo C, Smith SM, LaCasce A.
Author gender representation of journal reviews and editorials on lymphoma (2017-22).
The Lancet. 2023 Aug 12; 402(10401):523-525. https://doi.org/10.1016/S0140-6736(23)01428-9

Loo S, Roberts AW, Anstee NS, Kennedy GA, He SZ, Schwarer AP, Enjeti AK, D'Rozario J, Marlton P, Bilmon I, Taper JM, Cull G, Tiley C, Verner E, Hahn U, Hiwase DK, Iland HJ, Murphy NE, Ramanathan S, Reynolds J, Ong DM, Tiong IS, Wall M, Murray M, Rawling T, Leadbetter J, Rowley L, Latimer M, Yuen SLS, Ting SB, Fong CY, Morris KL, Bajel A, Seymour JF, Levis MJ, Wei AH.
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.
Blood. 2023 Aug 30;142(23):1960-1971. https://doi.org/10.1182/blood.2023020301

Josefsson EC, Ramström S, Thaler J, Lordkipanidzé M, Agbani EO, Alberio L, Bakchoul T, Bouchard BA, Camera M, Chen VM, Cognasse F.
Consensus report on markers to distinguish procoagulant platelets from apoptotic platelets: communication from the Scientific and Standardization Committee of the ISTH.
Journal of Thrombosis and Haemostasis. 2023 Aug; 21(8):2291-2299. https://doi.org/10.1016/j.jtha.2023.05.001

Dickinson M, Berkahn L, Trotman J, Butler J, Neeson P, Bressel M, Minson A.
P1066: Pembrolizumab Monotherapy As A First Therapy For Hodgkin Lymphoma Is Deliverable In Older Or Abvd Ineligible Patients, Does Not Preclude Subsequent Therapy, And Provides Adequate Survival.
HemaSphere. 2023 Aug;7(Suppl):e691267e. https://doi.org/10.1097/01.HS9.0000971160.69126.7e

Fleming S, Reynolds J, Bajel A, Venn N, Kwan J, Moore J, Yeung D, Pati N, Leahy M, Kollipara S, Verner E, Berkakn L, Sutton R, Wei A, Greenwood M.
P365: Sequential blinatumomab with reduced intensity chemotherapy for older adults with newly diagnosed ph-b-precursor acute lymphoblastic leukemia-final results of the ALLG ALL08 study.
HemaSphere. 2023 Aug;7(Suppl). e811479d. https://doi.org/10.1097/01.HS9.0000968372.81147.9d

Johnson N, Lavie D, Borchmann P, Gregory G, Herrera AF, Minuk L, Vucinic V, Armand P, Avigdor A, Gasiorowski R, Herishanu, Keane C, Kuruvilla J, Marceau West R, Pillai P, Marinello P, Timmerman J.
P1065: Updated results from an open-label phase 1/2 study of favezelimab in combination with pembrolizumab in patients with ANTI-PD-1-naive relapsed or refractory classical hodgkin lymphoma.
HemaSphere. 2023 Aug;7(Suppl):e0274602. https://doi.org/10.1097/01.hs9.0000971156.02746.02

Jurczak W, Ghesquieres H, Karimi Y, Cheah C, Clausen MR, Do YR, Lewis D, Gasiorowski R, Kim TM, Van Der Poel M, Poon ML, Feldman T, Linton K, Sureda A, Hutchings , Kanoun S, Vercellino L, Cota Stirner M, Mcgoldrick S, Liu Y, Sacchi M, Lugtenburg P, Thieblemont C.
P1118: Longer follow-up from the pivotal epcore NHL-1 trial reaffirms subcutaneous epcoritamab induces deep, durable complete remissions in patients with relapsed/refractory large b-cell lymphoma.
HemaSphere. 2023 Aug;7(Suppl). e081065c. https://doi.org/10.1097/01.HS9.0000971368.08106.5c

Minson A, Verner E, Giri P, Wong SM, Ratnasingam S, Butler J, Janowski W, Ku M, Cheah C, Hertzberg M, Herbert K. Nada Hamad,14 Costas Yannakou,15 Paul Neeson,1 Javad Saghebi,1 Piers Blombery,1 Molly Robertson,1 Lei Shong Lau,1 Jing Xie,1 John Seymour,1 and Michael Dickinson1.
P1117: GLOFITAMAB PLUS R-CHOP OR POLATUZUMAB VEDOTIN-R-CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS<= 65 YEARS OF AGE WITH HIGH-RISK DLBCL OR HGBL: INTERIM ANALYSIS OF THE COALITION STUDY.
HemaSphere. 2023 Aug;7(Suppl). e8608732. https://doi.org/10.1097/01.HS9.0000971364.86087.32

Munir T, Shadman M, Robak T, Brown JR, Kahl B, Ghia P, Giannopoulos K, Simkovic M, Österberg A, Laurenti L, Walker P, Opat S, Ciepluch H, Greil R, Hanna M, Tani M, Trneny M, Brander DM,20 Ian W. Flinn,21 Sebastian Grosicki,22 Emma Verner,23 Alessandra Tedeschi,25 Sophie De Guibert,26 Gayane Tumyan,27 Kamel Laribi,28 Jose Antonio Garcia Marco,29 Jianyong LI,30 Tian Tian,31 Vanitha Ramakrishnan,31 Yu Liu,31 Andy Szeto,31 Jason Paik,31 Aileen Cohen,31 Constantine Tam,32 and Wojciech Jurczak33.
P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE+ RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY.
Hemasphere. 2023 Aug;7(Suppl). e15364af. https://doi.org/10.1097/01.HS9.0000969460.15364.af

Opat S, Tedeschi A, Hu B, Linton K, Mckay P, Leitch S, Jin J, Sun M, Sobieraj-Teague M, Luigi Zinzani P, Browett P, Thieblemont C, Marina Liberati A, Bachy E, Cavallo F, Costello R, Iyengar S, Marasca R, Mociková H, Seok Kim J, Talaulikar D, Liang Z, Xu J, Tankersley C, Delarue R, Co M, Trotman J.
Long-Term Efficacy And Safety Of Zanubrutinib (Zanu) In Patients (Pts) With Relapsed/Refractory (R/R) Marginal Zone Lymphoma (Mzl): Final Analysis Of The Magnolia (Bgb-3111-214) Trial.
Hemasphere. 2023 Aug 8; 7(Suppl ):e77003b0. https://doi.org/10.1097/01.HS9.0000971232.77003.b0

Silvestre AS, Trotman J, Sarkozy C, Song Y, Sehn LH, Nastoupil LJ, Zhang W, Fustier P, Delarue R, Zinzani.
PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA.
HemaSphere. 2023 Aug;7(Suppl). e8253193. https://doi.org/10.1097/01.HS9.0000975836.58931.97

Tam C, Shadman M, Sharman J, Cull G, Phillips T, Trotman J, Cohen A, Allewelt H, Crescenzo R, Delarue R, Zhang H, Tariq B, Sahasranaman S, Ou YS, Flinn IW.
PB1926: EFFICACY AND SAFETY OF ONCE DAILY (QD) VS TWICE DAILY (BID) ZANUBRUTINIB FOR PATIENTS WITH VARIOUS B-CELL MALIGNANCIES: A COMPARATIVE SUMMARY OF CLINICAL DATA AND EXPOSURE-RESPONSE ANALYSES.
HemaSphere. 2023 Aug;7(Suppl). e70124b5. https://doi.org/10.1097/01.HS9.0000974528.70124.b5

Trotman J, Zinzani PL, Mayer J, Flowers C, Bijou F, Oliveira AC, Bouabdallah K, Johnson R, Garcia-Sancho AM, Pulla MP, Trneny M.
P1080: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY.
HemaSphere. 2023 Aug;7(Suppl). e2687131. https://doi.org/10.1097/01.HS9.0000971216.26871.31

Verner E, Johnston A, Pati N, Hawkes E, Lee HP, Cochrane T, Cheah CY, Filshie R, Purtill D, Sia H, Enjeti AK, Brown C, Murphy N, Curnow J, Lee K, Gandhi M, Butcher B, Trotman J.
P1127: FINAL ANALYSIS OF AUSTRALASIAN LEUKAEMIA & LYMPHOMA GROUP NHL29: A PHASE II STUDY OF IBRUTINIB, RITUXIMAB AND MINI-CHOP IN VERY ELDERLY PATIENTS WITH NEWLY DIAGNOSED DLBCL.
HemaSphere. 2023 Aug;7(Suppl). e129974b https://doi.org/10.1097/01.hs9.0000971404.12997.4b

Barraclough A, England JT, Villa D, Wight J, Hapgood G, Conn J, Wong Doo N, Li EW, Gilbertson M, Shaw B, Bishton MJ, Saeed M, Ratnasingam S, Abeyakoon C, Chong G, Wai SH, Ku M, Lee HP, Fleming K, Tam C, Douglas G, Cheah CY, Ng ZY, Rolfe T, Mills AK, Hamad N, Cashman H, Gleeson M, Narayana M, Hawkes EA.
Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance.
Haematologica. 2023 Sep 1;108(9):2444-2453. https://doi.org/10.3324/haematol.2022.281375

Epperla N, Kumar A, Abutalib SA, Awan FT, Gopal AK, Holter-Chakrabarty J, Kekre N, Lee CJ, Lekakis L, Lin Y, Matthew M, Nathan S, Nastoupil L, Oluwole O, Phillips AA, Reid E, Rezvani AR, Trotman J, Zurko J, Kharfan-Dabaja MA, Sauter CS, Perales MA, Locke FL, Carpenter PA, Hamadani M.
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma. Transplantation and Cellular Therapy.
Transplantation and Cellular Therapy. 2023 Sep 1; 29(9):548-555. https://doi.org/10.1016/j.jtct.2023.06.012

Karimi Y, Ghesquieres H, Jurczak W, Cheah CY, Clausen MR, Lugtenburg P, Do YR, Lewis DJ, Gasiorowski R, Kim TM, van der Poel M, Poon ML, Feldman T, Linton KM, Sureda A, Hutchings M, Stirner MC, Liu Y, Kilavuz N, Thieblemont C.
ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial.
Clinical Lymphoma, Myeloma and Leukemia. 2023 Sep 1;23:S438. https://doi.org/10.1016/S2152-2650(23)01330-7

Opat S, Tedeschi A, Hu B, Linton KM, McKay P, Leitch S, Coleman M, Zinzani PL, Jin J, Sun M, Sobieraj-Teague M. Browett P, Ke X, Thieblemont C, Ardeshna K, Bijou F, Walker P, Hawkes EA, Ho SJ, Zhou K, Liang Z, Xu J, Tankersley C, Delarue R, Co M, Trotman J.
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.
Blood Advances. 2023 Sep 21; https://doi.org/10.1182/bloodadvances.2023010668

Cheah S, Bassett JK, Bruinsma FJ, Hopper J, Jayasekara H, Joshua D, MacInnis RJ, Prince HM, Southey MC, Vajdic CM, van Leeuwen MT, Wong Doo N, Harrison SJ, English DR, Giles GG, Milne RL.
Modifiable lifestyle risk factors and survival after diagnosis with multiple myeloma.
Expert Review of Hematology. 2023 Oct 3; 16(10);773-783. https://doi.org/10.1080/17474086.2023.2255747

Luminari S, Fossa A, Trotman J, Molin D, d'Amore F, Enblad G, Berkahn L, Barrington SF, Radford J, Federico M, Kirkwood AA.
Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial.
Journal of Clinical Oncology. 2023 Oct; JCO-23:1-13. https://doi.org/10.1200/JCO.23.01177

Mascuñano RC, Cheah CY, Tam CS, Lasica M, Verner E, Browett PJ, Anderson MA, Hilger J, Fang Y, Simpson D, Opat S.
Phase 1 Study With the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor Sonrotoclax (BGB-11417) as Monotherapy or in Combination With Zanubrutinib for CLL/SLL: Preliminary Data.
Sangre. 2023 Oct; 42(1): 268. Presented at LXV Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia (SEHH); October 26-28, 2023; Seville, Spain.

Odutola MK, van Leeuwen MT, Bruinsma FJ, Benke G, Turner MC, Trotman J, Turner J, Seymour JF, Prince HM, Milliken ST, Tiley C, Hertzberg M, Roncolato F, Opat S, Lindeman R, Verner E, Underhill CR, Cardis E, Giles G, Vajdic CM.
Occupational exposure to extremely low-frequency magnetic fields and follicular lymphoma risk: a family case-control study.
Occupational and Environmental Medicine. 2023 Oct;80(10):599-602. https://doi.org/10.1136/oemed-2023-108949

Tran HA, Deng L, Wood N, Choi P, Singleton S, Clarke L, Khanlari S, Maitland-Scott I, Bird R, Brown S, Manoharan B, Tan CW, Gold M, Hissaria P, Melody S, Chunilal SD, Buttery J, Clothier H, Crawford NW, Phuong L, Pepperell D, Effler P, Parker C, Carter N, Macartney K, McStea M, Miller T, Nissen M, Larter C, Kay E, Chen VM.
The clinicopathological features of thrombosis with thrombocytopenia syndrome following ChAdOx1-S (AZD1222) vaccination and case outcomes in Australia: a population-based study.
The Lancet Regional Health - Western Pacific. 2023 Nov 1;40. https://doi.org/10.1016/j.lanwpc.2023.100894

Garcia-Manero G, Odenike O, Fleming S, Roboz GJ, Jacoby M, Cunningham I, Kreuzer KA, Enjeti AK, Baer MA, Cook R, Jurcic J, Ku G, Zhou Y, Hoffman D, Potluri J, Garcia JS.
Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation.
Blood. 2023 Nov 02; 142(1): 1868. https://doi.org/10.1182/blood-2023-187102

Tam C, Anderson MA, Lasica M, Verner E, Opat SS, Ma S, Weinkove R, Cordoba R, Soumerai J, Chia P, Leitch S, Hilger J, Fang Y, Simpson D, Guo H, Cheah CY.
Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL): Data from an Ongoing Phase 1/2 Study.
Blood. 2023 Nov 02; 142(1): 327. https://doi.org/10.1182/blood-2023-179541

Tedeschi A, Cheah CY, Opat SS, Verner E, Magnano L, Epperla N, Hilger J, Fang Y, Simpson D, Guo H, Anderson MA.
Monotherapy with Second-Generation BCL2 Inhibitor Sonrotoclax (BGB-11417) Is Well Tolerated with High Response Rates in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Data from an Ongoing Phase 1 Study.
Blood. 2023 Nov 02; 142(1): 3032. https://doi.org/10.1182/blood-2023-178841

Yeung DT, Shanmuganathan N, Reynolds J, Branford S, Walia M, Yong A, Shortt J, Burbury K, Chee L, Viiala N, Cunningham I, Ross DM, D'Souza AB, Wright M, Harrup RA, Forsyth C, Filshie R, Browett PJ, Lane S, Grove C.
Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study.
Blood. 2023 Nov 02; 142(1): 865. https://doi.org/10.1182/blood-2023-172583

Al-Mashhadi AL, Simonsen MR, Cheah CY, Amini RM, Arboe B, Cerhan JR, Chanchiri I, Clausen MR, Day J, Eyre TA, Ortved Gang A, Ghesquieres H, Habermann TM, Hawkes EA, Hwang SR, Jørgensen JB, Khurana A, Maquet C, Layshe N, Opat SS, El-Galaly TC.
Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up.
Blood. 2023 Nov 28; 142(1): 4396. https://doi.org/10.1182/blood-2023-173247

Johnson NA, Lavie D, Borchmann P, Gregory GP, Herrera AF, Minuk L, Vucinic V, Armand P, Avigdor A, Gasiorowski R, Herishanu Y, Keane C, Kuruvilla J, Marceau West R, Pillai P, Marinello P, Timmerman J
A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies.
Blood. 2023 Nov 28; 142(1): 1693. https://doi.org/10.1182/blood-2023-182128

Phillips EH, Kirkwood AA, Hague C, Vestbo J, Federico M, D'Amore F, Fossa A, Trotman J, Berkahn L, Molin DL, Luminari S, Barrington SF, Johnson P, Radford J.
Bleomycin Affects Lung Function for at Least 5 Years after Treatment for Hodgkin Lymphoma - Data from the International, Randomised Phase 3 Rathl Trial.
Blood. 2023 Nov 28; 142(1): 612. https://doi.org/10.1182/blood-2023-185818

Santoro A, Johnson NA, Savage KJ, Avigdor A, Bazargan A, Borchmann P, Gasiorowski R, Gregory GP, Herishanu Y, Madan S, Minuk L, Musuraca G, Marceau West R, Pillai P, Marinello P, Zinzani PL.
Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study.
Blood. 2023 Nov 28; 142(1): 1725. https://doi.org/10.1182/blood-2023-182536

Seymour JF, Cheah CY, Parrondo R, Thompson MC, Stevens DA, Lasica M, Wang ML, Kumar A, Trotman J, Alwan M, Ding W, By K, Tariq B, Chen X, Fabre S, Paik J, Agarwal A, Tam CS.
First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101).
Blood. 2023 Nov 28; 142(1): 4401. https://doi.org/10.1182/blood-2023-180109

Tobin JWD, Chowdhury R, Salvaris R, Griffin A, Chikatamarla V, Goh A, Tong TH, Birks C, Jain S, Goodall E, Sirdesai S, Trevis T, Elizabeth S, Chen Y, Black H, Broadby G, Li L, Gutta N, Morris KL, Cochrane T, Hapgood G.
The Nature of High-Risk Defining Events in Follicular Lymphoma Determines Overall Survival.
Blood. 2023 Nov 28; 142(1): 1671. https://doi.org/10.1182/blood-2023-185879

Tohidi-Esfahani I, Xing Y, Venturelli V, Gavriilaki E, Kang X, Isenberg D, Cohen H, Efthymiou M.
Complement Activation Is Increased in Antiphospholipid Syndrome-Related Ischemic Stroke with Higher Risk Features.
Blood. 2023 Nov 28; 142(2): 3943. https://doi.org/10.1182/blood-2023-182287

Trotman J, Zinzani PL, Song Y, Delarue R, Barnes G, Kim P, Ivanova E, Tang B, Mayer J, De Oliveira AC, Assouline S, Flowers CR.
Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated with Zanubrutinib+ Obinutuzumab Versus Obinutuzumab Monotherapy: The Rosewood Trial.
Blood. 2023 Nov 28; 142(1): 1674. https://doi.org/10.1182/blood-2023-181195

Wood EM, Chai KL, Reynolds J, Griffiths J, Beaton B, Callum J, Crassini KR, Crispin PJ, Fanning L, Gilbertson M, Grigg AP, Hawkes EA, Morrissey CO, Mulligan SP, Opat SS, Paterson DL, Petrie D, Roberts JA, Ryan EG, Spencer A,McQuilten ZK.
Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II/III Rational Platform Trial, and the Rationalise (STOP IgRT) Domain.
Blood. 2023 Nov 28; 142(1): 1295. https://doi.org/10.1182/blood-2023-181541

Wilson MR, Kirkwood AA, Wong Doo N, Soussain C, Choquet S, Lees C, Fox C, Preston G, Ahearne M, Strüßmann T, Clavert A, Rusconi C, Ku M, Khwaja J, Narkhede M, Lewis K, Durot E, Smith J, Renaud L, Ferreri AJM, El-Galaly T, Cwynarski K, McKay P, Eyre TA.
Dosage of high-dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse.
American Journal of Hematology. 2023 Nov 30; 99(2):E46-50. https://doi.org/10.1002/ajh.27167

Kostakoglu L, Martelli M, Sehn LH, Davies A, Trněný M, Herold M, Vitolo U, Hiddemann W, Trotman J, Knapp A, Mattiello F, Nielsen TG, Sahin D, Sellam G, Ward C, Younes A.
A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials.
European Journal of Haematology. 2023 Nov; 4(4): 1042-1051. https://doi.org/10.1002/jha2.796

Zlamal J, Aliotta A, Alberio L, Chen VM, Bakchoul T.
Diagnostic value of antibody-induced procoagulant platelets in heparin-induced thrombocytopenia: communication from the ISTH SSC Subcommittee on Platelet Immunology.
Journal of Thrombosis and Haemostasis. 2023 Dec 06; p1-9. https://doi.org/10.1016/j.jtha.2023.11.019

2022

Kalff A, Khong T, Ramachandran M, Ho PJ, Mollee P, D'Rozario J, Taylor K, Estell J, Norton S, Kemp R, Mitchell AJ, Reynolds J, Kennedy N, Quach H, Spencer A.
Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14).
Haematologica. 2022 Jan 1; 107(1):321-325. doi: 10.3324/haematol.2021.278655.

Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas R-O, Ysebaert L, Damaj G, Guidez S, Pica GM, Kim WS, Lim ST, André M, García-Sancho AM, Penarrubia MJ, Staber PB, Trotman J, Hüttmann A, Stefoni V, Re A, Gaulard P, Delfau-Larue M-H, de Level L, Meignan M, Li J, Morschhauser F, Delarue R.
Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA).
Journal of Clinical Oncology, 2022 January; 40 (3): 242-251. https://doi.org/10.1200/JCO.21.01815

Buske C, Tedeschi A, Trotman J, García-Sanz R, MacDonald D, Leblond V, Mahe B, Herbaux C, Matous JV, Tam CS, Heffner LT, Varettoni M, Palomba ML, Shustik C, Kastritis E, Treon SP, Ping J, Hauns B, Arango-Hisijara I, Dimopoulos MA.
Ibrutinib plus rituximab versus placebo plus rituximab for Waldenström's macroglobulinemia: final analysis from the randomized phase III iNNOVATE study.
Journal of Clinical Oncology, 2022 Jan 1; 40 (1): 52-62(11); https://doi.org/10.1200/JCO.21.00838

Cartron G, Trotman J.
Time for an individualized approach to first-line management of follicular lymphoma.
Haematologica. 2022 Jan 1; 107(1): 7-18. doi: 10.3324/haematol.2021.278766.

Tam CS, Dimopoulos M, Garcia-Sanz R, Trotman J, Opat S, Roberts AW, Owen R, Song Y, Xu W, Zhu J, Li J, Qiu L, D'Sa S, Jurczak W, Cull G, Marlton P, Gottlieb D, Munoz J, Phillips T, Du C, Ji M, Zhou L, Guo H, Zhu H, Chan WY, Cohen A, Novotny W, Huang J, Tedeschi A.
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies.
Blood Adv. 2022 Feb 22;6(4):1296-1308. doi: 10.1182/bloodadvances.2021005621.

Connor D, Rabbolini D, Morel-Kopp MC, Fixter K, Donikian D, Kondo M, Chan O, Jarvis S, Chen W, Brighton T, Chen V, Ward C, Joseph J.
The utility of flow cytometric platelet forward scatter as an alternative to mean platelet volume.
Platelets. 2022 Nov 17;33(8):1139-1145. doi: 10.1080/09537104.2022.2052035. Epub 2022 Mar 22.

Chen V, Akhtar S, Zheng C, Kumaresan V, Nouri K.
Assessment of Changes in Diversity in Dermatology Clinical Trials Between 2010-2015 and 2015-2020: A Systematic Review.
JAMA Dermatol. 2022 Mar 1;158(3):288-292. doi: 10.1001/jamadermatol.2021.5596.

Cull G, Burger JA, Opat S, Gottlieb D, Verner E, Trotman J, Marlton P, Munoz J, Johnston P, Simpson D, Stern JC, Prathikanti R, Wu K, Novotny W, Huang J, Tam CS.
Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
Br J Haematol. 2022 Mar;196(5):1209-1218. doi: 10.1111/bjh.17994.

Trotman J, Pettitt AR.
Is it time for PET-guided therapy in follicular lymphoma?
Blood. 2022 Mar 17;139(11):1631-1641. doi: 10.1182/blood.2020008243.

Harrop S, Di Ciaccio P, Doo NW, Cochrane T, Campbell BA, Hamad N, Dickinson M, Van Der Weyden C, Prince HM.
The gamma delta lymphomas: an Australian multi-centre case series.
Annals of Lymphoma, 2022;6:3. doi: 10.21037/aol-21-41

Marks DI, Kirkwood AA, Rowntree CJ, Aguiar M, Bailey KE, Beaton B, Cahalin P, Castleton AZ, Clifton-Hadley L, Copland M, Goldstone AH, Kelly R, Lawrie E, Lee S, McMillan AK, McMullin MF, Menne TF, Mitchell RJ, Moorman AV, Patel B, Patrick P, Smith P, Taussig D, Yallop D, Alapi KZ, Fielding AK.
Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial.
Lancet Haematol. 2022 Apr;9(4):e262-e275. doi: 10.1016/S2352-3026(22)00038-2.

Dix C, McFadyen J, Huang A, Chunilal S, Chen V, Tran H.
Understanding vaccine-induced thrombotic thrombocytopenia (VITT).
Intern Med J. 2022 May;52(5):717-723. doi: 10.1111/imj.15783.

Rabbolini D, Liang HPH, Morel-Kopp MC, Connor D, Whittaker S, Dunkley S, Donikian D, Kondo M, Chen W, Stevenson WS, Campbell H, Joseph J, Ward C, Brighton T, Chen VM; Sydney Platelet Group.
Building platelet phenotypes: Diaphanous-related formin 1 (DIAPH1)-related disorder.
Platelets. 2022 Apr 3;33(3):432-442. doi: 10.1080/09537104.2021.1937593.

Pennings GJ, Reddel CJ, Traini M, Lam M, Kockx M, Chen VM, Kritharides L.
Rapid Release of Interleukin-1β from Human Platelets Is Independent of NLRP3 and Caspase.
Thromb Haemost. 2022 Apr;122(4):517-528. doi: 10.1055/s-0041-1731288.

Lee CSM, Selvadurai MV, Pasalic L, Yeung J, Konda M, Kershaw GW, Favaloro EJ, Chen VM.
Measurement of procoagulant platelets provides mechanistic insight and diagnostic potential in heparin-induced thrombocytopenia.
J Thromb Haemost. 2022 Apr;20(4):975-988. doi: 10.1111/jth.15650. Epub 2022 Feb 7.

Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N.
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.
N Engl J Med. 2022 Apr 14;386(15):1421-1431. doi: 10.1056/NEJMoa2110297.

Wilson MR, Eyre TA, Kirkwood AA, Wong Doo N, Soussain C, Choquet S, Martinez-Calle N, Preston G, Ahearne M, Schorb E, Moles-Moreau MP, Ku M, Rusconi C, Khwaja J, Narkhede M, Lewis KL, Calimeri T, Durot E, Renaud L, Øvlisen AK, McIlroy G, Ebsworth TJ, Elliot J, Santarsieri A, Ricard L, Shah N, Liu Q, Zayac AS, Vassallo F, Lebras L, Roulin L, Lombion N, Manos K, Fernandez R, Hamad N, Lopez-Garcia A, O'Mahony D, Gounder P, Forgeard N, Lees C, Agbetiafa K, Strüßmann T, Htut TW, Clavert A, Scott H, Guidetti A, Barlow BR, Tchernonog E, Smith J, Miall F, Fox CP, Cheah CY, El Galaly TC, Ferreri AJM, Cwynarski K, McKay P.
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.
Blood. 2022 Apr 21;139(16):2499-2511. doi: 10.1182/blood.2021014506.

Islam S, Cullen T, Sumpton D, Damodaran A, Heath D, Bosco A, Wong Doo N, Kidson-Gerber G, Cheong A, Lawford R, Walsh R, Sammel A.
VEXAS syndrome: lessons learnt from an early Australian case series.
IMJ. 2022 Apr;52(4):658-662. doi: 10.1111/imj.15742.

Gasiorowski R, Forbes MK, Silver G, Krastev Y, Hamdorf B, Lewis B, Tisbury M, Cole-Sinclair M, Lanphear BP, Klein RA, Holmes N, Taylor MP.
Effect of Plasma and Blood Donations on Levels of Perfluoroalkyl and Polyfluoroalkyl Substances in Firefighters in Australia: A Randomized Clinical Trial.
JAMA Netw Open. 2022 Apr 1;5(4):e226257. doi: 10.1001/jamanetworkopen.2022.6257.

Choi PY, Hsu D, Tran HA, Tan CW, Enjeti A, Chen VMY, Chong BH, Curnow J, Pepperell D, Bird R.
Immune thrombocytopenia following vaccination during the COVID-19 pandemic.
Haematologica. 2022 May 1;107(5):1193-1196. doi: 10.3324/haematol.2021.279442.

Odutola MK, van Leeuwen MT, Turner J, Bruinsma F, Seymour JF, Prince HM, Milliken ST, Trotman J, Verner E, Tiley C, Roncolato F, Underhill CR, Opat SS, Harvey M, Hertzberg M, Benke G, Giles GG, Vajdic CM.
Associations between Smoking and Alcohol and Follicular Lymphoma Incidence and Survival: A Family-Based Case-Control Study in Australia.
Cancers (Basel). 2022 May 30;14(11):2710. doi: 10.3390/cancers14112710.

Lee CSM, Liang HPH, Connor DE, Dey A, Tohidi-Esfahani I, Campbell H, Whittaker S, Capraro D, Favaloro EJ, Donikian D, Kondo M, Hicks SM, Choi PY, Gardiner EE, Clarke LJ, Tran H, Passam FH, Brighton TA, Chen VM.
A novel flow cytometry procoagulant assay for diagnosis of vaccine-induced immune thrombotic thrombocytopenia.
Blood Adv. 2022 Jun 14;6(11):3494-3506. doi: 10.1182/bloodadvances.2021006698. PMID: 35359002

Yeung D, Grigg A, Shanmuganathan N, Soltenbeck A, White D, Branford S, Viiala N, Rowlings P, Mills A, Shortt J, C Tiley, Ross D, Kipp D, Harrup R, Cunningham I, Kwan J, Eek R, Mutsando H, Tan K-S, Burbury K, Wright M, Hughes T.
PROACTIVE DASATINIB DOSE REDUCTION IN THE ALLG CML 12 DIRECT STUDY BASED ON TROUGH LEVELS MINIMISE TOXICITY AND PRESERVE EFFICACY
HemaSphere 6():p 615-616, June 2022. | DOI: 10.1097/01.HS9.0000845764.61186.15

Wong J, Gruber E, Maher B, Waltham M, Sabouri-Thompson Z, Jong I, Luong Q, Levy S, Kumar B, Brasacchio D, Jia W, So J, Skinner H, Lewis A, Hogg SJ, Vervoort S, DiCorleto C, Uhe M, Gamgee J, Opat S, Gregory GP, Polekhina G, Reynolds J, Hawkes EA, Kailainathan G, Gasiorowski R, Kats LM, Shortt J.
Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.
Leukemia. 2022 Jun;36(6):1654-1665. doi: 10.1038/s41375-022-01571-8.

Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernández-Rivas JÁ, Hong X, Kim SJ, Lewis D, Mishima Y, Özcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storring JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S, Dreyling M; SHINE Investigators.
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
N Engl J Med. 2022 Jun 30;386(26):2482-2494. doi: 10.1056/NEJMoa2201817.

Phillips T, Chan H, Tam CS, Tedeschi A, Johnston P, Oh SY, Opat S, Eom HS, Allewelt H, Stern JC, Tan Z, Novotny W, Huang J, Trotman J.
Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.
Blood Adv. 2022 Jun 14;6(11):3472-3479. doi: 10.1182/bloodadvances.2021006083.

Reddel CJ, Pennings GJ, Chen VM, Gnanenthiran S, Kritharides L.
Colchicine as a Modulator of Platelet Function: A Systematic Review.
Semin Thromb Hemost. 2022 Jul;48(5):552-567. doi: 10.1055/s-0042-1749660.

Xu W, Yang S, Tam CS, Seymour JF, Zhou K, Opat S, Qiu L, Sun M, Wang T, Trotman J, Pan L, Gao S, Zhou J, Zhou D, Zhu J, Song Y, Hu J, Feng R, Huang H, Su D, Shi M, Li J.
Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies.
Adv Ther. 2022 Sep;39(9):4250-4265. doi: 10.1007/s12325-022-02238-7.

Gnanenthiran SR, Pennings GJ, Reddel CJ, Campbell H, Kockx M, Hamilton JR, Chen VM, Kritharides L.
Identification of a Distinct Platelet Phenotype in the Elderly: ADP Hypersensitivity Coexists With Platelet PAR (Protease-Activated Receptor)-1 and PAR-4-Mediated Thrombin Resistance.
Arterioscler Thromb Vasc Biol. 2022 Aug;42(8):960-972. doi: 10.1161/ATVBAHA.120.316772.

Gasiorowski R, Trotman J.
CAR-T for follicular lymphoma: are we good to go?
Blood. 2022 Aug 25;140(8):799-800. doi: 10.1182/blood.2022017279.

Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, Šimkovič M, Shadman M, Österborg A, Laurenti L, Walker P, Opat S, Chan H, Ciepluch H, Greil R, Tani M, Trněný M, Brander DM, Flinn IW, Grosicki S, Verner E, Tedeschi A, Li J, Tian T, Zhou L, Marimpietri C, Paik JC, Cohen A, Huang J, Robak T, Hillmen P.
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Lancet Oncol. 2022 Aug;23(8):1031-1043. doi: 10.1016/S1470-2045(22)00293-5.

Barrington SF, Mir F, El-Galaly TC, Knapp A, Nielsen TG, Sahin D, Wenger M, Kostakoglu L, Trotman J, Meignan M.
Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study.
J Nucl Med. 2022 Aug;63(8):1149-1154. doi: 10.2967/jnumed.121.262869.

Pastar I, Balukoff NC, Marjanovic J, Chen VY, Stone RC, Tomic-Canic M.
Molecular Pathophysiology of Chronic Wounds: Current State and Future Directions.
Cold Spring Harb Perspect Biol. 2022 Sep 19:a041243. doi: 10.1101/cshperspect.a041243.

Wight J, Hamad N, Campbell BA, Ku M, Lee K, Rose H, Armytage T, Latimer M, Lee HP, Lee ST, Dickinson M, Khor R, Verner E.
Diffuse large B-cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.
Intern Med J. 2022 Sep;52(9):1609-1623. doi: 10.1111/imj.15533.

Nowakowski GS, Yoon DH, Peters A, Mondello P, Joffe E, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Huang D, Waltl EE, Winderlich M, Kurukulasuriya NC, Ambarkhane S, Hess G, Salles G.
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.
Clin Cancer Res. 2022 Sep 15;28(18):4003-4017. doi: 10.1158/1078-0432.CCR-21-3648.

Odutola MK, van Leeuwen MT, Turner J, Bruinsma F, Seymour JF, Prince HM, Milliken ST, Hertzberg M, Trotman J, Opat SS, Lindeman R, Roncolato F, Verner E, Harvey M, Tiley C, Underhill CR, Benke G, Giles GG, Vajdic CM.
Associations between early-life growth pattern and body size and follicular lymphoma risk and survival: a family-based case-control study.
Cancer Epidemiol. 2022 Oct;80:102241. doi: 10.1016/j.canep.2022.102241.

Kershaw G, Dix C, Chen VM, Cai N, Khoo TL.
Emicizumab assay evaluations and results from an Australian field study of emicizumab measurement.
Pathology. 2022 Oct;54(6):755-762. doi: 10.1016/j.pathol.2022.02.006.

Nath CE, Grigg A, Rosser SPA, Estell J, Newman E, Tiley C, Ramanathan S, Ho SJ, Larsen S, Gibson J, Presgrave P, Shaw PJ, Trotman J.
Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myeloma.
Eur J Clin Pharmacol. 2022 Dec;78(12):1911-1921. doi: 10.1007/s00228-022-03396-x.

Adattini JA, Gross AS, Wong Doo N, McLachlan AJ.
Real-world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience.
Pharmacol Res Perspect. 2022 Oct;10(5):e01005. doi: 10.1002/prp2.1005.

Li EW, Krishnaswamy M, El-Wahsh S, Balgobind S, Trotman J, Tan I, Hardy TA.
Paraneoplastic primary CNS angiitis secondary to nodular lymphocyte predominant Hodgkin lymphoma.
Pathology. 2022 Oct 29:S0031-3025(22)00278-1. doi: 10.1016/j.pathol.2022.08.012.

Trotman J, Lymphoma and Related Diseases Registry Investigators.
Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry.
BMC Med Res Methodol. 2022 Oct 10;22(1):266. doi: 10.1186/s12874-022-01728-0.

Ellis ML, Alwis I, Smythe R, Yuan Y, Jackson SP.
Megakaryocyte buds are distinct from microvesicles and likely to represent platelet precursors.
Blood Adv. 2022 Nov 10:bloodadvances.2022008850. doi: 10.1182/bloodadvances.2022008850.

de Leval L, Alizadeh AA, Bergsagel PL, Campo E, Davies A, Dogan A, Fitzgibbon J, Horwitz SM, Melnick AM, Morice WG, Morin RD, Nadel B, Pileri SA, Rosenquist R, Rossi D, Salaverria I, Steidl C, Treon SP, Zelenetz AD, Advani RH, Allen CE, Ansell SM, Chan WC, Cook JR, Cook LB, d'Amore F, Dirnhofer S, Dreyling M, Dunleavy K, Feldman AL, Fend F, Gaulard P, Ghia P, Gribben JG, Hermine O, Hodson DJ, Hsi ED, Inghirami G, Jaffe ES, Karube K, Kataoka K, Klapper W, Kim WS, King RL, Ko YH, LaCasce AS, Lenz G, Martin-Subero JI, Piris MA, Pittaluga S, Pasqualucci L, Quintanilla-Martinez L, Rodig SJ, Rosenwald A, Salles GA, San-Miguel J, Savage KJ, Sehn LH, Semenzato G, Staudt LM, Swerdlow SH, Tam CS, Trotman J, Vose JM, Weigert O, Wilson WH, Winter JN, Wu CJ, Zinzani PL, Zucca E, Bagg A, Scott DW.
Genomic profiling for clinical decision making in lymphoid neoplasms.
Blood. 2022 Nov 24;140(21):2193-2227. doi: 10.1182/blood.2022015854.

Trotman J.
Key points from the SHINE trial in mantle cell lymphoma.
Clin Adv Hematol Oncol. 2022 Nov;20(11):652-654.

Talaulikar D, Joshua D, Ho PJ, Gibson J, Quach H, Gibbs S, Ling S, Ward C, Augustson B, Trotman J, Harrison SJ, Tam CS; Medical and Scientific Advisory Group, Myeloma Australia.
Treatment of Patients with Waldenström Macroglobulinaemia: Clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Intern Med J. 2022 Nov 28. doi: 10.1111/imj.15980.

Favaloro EJ, Clifford J, Leitinger E, Parker M, Sung P, Chunilal S, Tran H, Kershaw G, Fu S, Passam F, Ahuja M, Ho SJ, Duncan E, Yacoub O, Tan CW, Kaminskis L, Modica N, Pepperell D, Ballard L, Clarke L, Lee CSM, Gardiner EE, Young-Ill Choi P, Tohidi-Esfahani I, Bird R, Brighton T, Chen VM.
Assessment of immunological anti-platelet factor 4 antibodies for vaccine-induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: A multicenter study comprising 1284 patients.
J Thromb Haemost. 2022 Dec;20(12):2896-2908. doi: 10.1111/jth.15881.

Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman T, Gasiorowski R, Jurczak W, Kim TM, Lewis DJ, van der Poel M, Poon ML, Cota Stirner M, Kilavuz N, Chiu C, Chen M, Sacchi M, Elliott B, Ahmadi T, Hutchings M, Lugtenburg PJ.
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
J Clin Oncol. 2022 Dec 22:JCO2201725. doi: 10.1200/JCO.22.01725.

Berndt SI, Vijai J, Benavente Y, Camp NJ, Nieters A, Wang Z, Smedby KE, Kleinstern G, Hjalgrim H, Besson C, Skibola CF, Morton LM, Brooks-Wilson AR, Teras LR, Breeze C, Arias J, Adami HO, Albanes D, Anderson KC, Ansell SM, Bassig B, Becker N, Bhatti P, Birmann BM, Boffetta P, Bracci PM, Brennan P, Brown EE, Burdett L, Cannon-Albright LA, Chang ET, Chiu BCH, Chung CC, Clavel J, Cocco P, Colditz G, Conde L, Conti DV, Cox DG, Curtin K, Casabonne D, De Vivo I, Diver WR, Dogan A, Edlund CK, Foretova L, Fraumeni JF Jr, Gabbas A, Ghesquières H, Giles GG, Glaser S, Glenn M, Glimelius B, Gu J, Habermann TM, Haiman CA, Haioun C, Hofmann JN, Holford TR, Holly EA, Hutchinson A, Izhar A, Jackson RD, Jarrett RF, Kaaks R, Kane E, Kolonel LN, Kong Y, Kraft P, Kricker A, Lake A, Lan Q, Lawrence C, Li D, Liebow M, Link BK, Magnani C, Maynadie M, McKay J, Melbye M, Miligi L, Milne RL, Molina TJ, Monnereau A, Montalvan R, North KE, Novak AJ, Onel K, Purdue MP, Rand KA, Riboli E, Riby J, Roman E, Salles G, Sborov DW, Severson RK, Shanafelt TD, Smith MT, Smith A, Song KW, Song L, Southey MC, Spinelli JJ, Staines A, Stephens D, Sutherland HJ, Tkachuk K, Thompson CA, Tilly H, Tinker LF, Travis RC, Turner J, Vachon CM, Vajdic CM, Van Den Berg A, Van Den Berg DJ, Vermeulen RCH, Vineis P, Wang SS, Weiderpass E, Weiner GJ, Weinstein S, Doo NW, Ye Y, Yeager M, Yu K, Zeleniuch-Jacquotte A, Zhang Y, Zheng T, Ziv E, Sampson J, Chatterjee N, Offit K, Cozen W, Wu X, Cerhan JR, Chanock SJ, Slager SL, Rothman N.
Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes.
Leukemia. 2022 Dec;36(12):2835-2844. doi: 10.1038/s41375-022-01711-0.

Nguyen J, Wellard C, Chung E, Cheah CY, Dickinson M, Doo NW, Keane C, Talaulikar D, Berkahn L, Morgan S, Hamad N, Cochrane T, Johnston AM, Forsyth C, Opat S, Barraclough A, Mutsando H, Ratnasingam S, Giri P, Wood EM, McQuilten ZK, Hawkes EA; Lymphoma and Related Diseases Registry investigators.
Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry.
Eur J Haematol. 2022 Dec 20. doi: 10.1111/ejh.13915.

Tariq B, Ou YC, Stern JC, Mundra V, Wong Doo N, Walker P, Lewis KL, Lin C, Novotny W, Sahasranaman S, Opat S.
A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies.
Leuk Lymphoma. 2022 Dec 8:1-10. doi: 10.1080/10428194.2022.2150820.

Haematology Research

Our Key Research Themes and Achievements

Patient and Community Philanthropic Support

MyHodgkin MyHealth

Our Research Team

Selected Grants

Our Publications

2024

Haematology Research

Haematology Research

Our Organisation

Make a Donation

Our Hospitals

Care in our Community

Right to Information

Your feedback

Plans

Publications

Quick Links